Table 1 Body mass index (kg/m2) in relation to all-cause mortality and prostate cancer-specific mortality stratified by smoking status in the Prostate Cancer Cohort Study in Alberta, Canada, 1997–2017

From: Reply to ‘Comment on ‘Anthropometric measurements and survival after prostate cancer diagnosis”

Smoking status by BMI category

All-cause mortality

Prostate cancer-specific mortality

All-cause deaths/cases

Age-adjusted HR (95% CI)

Multivariable adjusted HR (95% CI)a

Prostate cancer deaths/cases

Age-adjusted HR (95% CI)

Multivariable adjusted HR (95% CI)b

Baseline (within 6 months; n = 987)

Never

 <25

35/60

1.0

1.0

16/60

1.0

1.0

 25 ≤ 30

94/146

1.22 (0.83–1.80)

1.14 (0.76–1.71)

39/146

1.05 (0.59–1.88)

0.72 (0.38–1.34)

 30+

41/69

1.36 (0.86–2.15)

1.37 (0.86–2.19)

22/69

1.29 (0.68–2.48)

1.12 (0.57–2.22)

 Test for trend

 

0.18

0.19

 

0.42

0.66

Former

 <25

66/94

1.0

1.0

19/94

1.0

1.0

 25 ≤ 30

179/289

0.89 (0.67–1.18)

0.77 (0.58–1.03)

60/289

0.99 (0.59–1.67)

0.76 (0.44–1.29)

 30+

128/183

1.21 (0.90–1.64)

1.00 (0.74–1.37)

57/183

1.73 (1.02–2.92)

1.33 (0.76–2.31)

 Test for trend

 

0.08

0.53

 

0.007

0.06

Current

 <25

47/59

1.0

1.0

18/59

1.0

1.0

 25 ≤ 30

43/58

0.85 (0.56–1.29)

0.98 (0.62–1.55)

14/58

0.74 (0.37–1.50)

0.94 (0.42–2.06)

 30+

23/29

1.30 (0.78–2.15)

1.38 (0.81–2.35)

7/29

0.90 (0.37–2.15)

1.11 (0.42–2.90)

 Test for trend

 

0.54

0.31

 

0.64

0.89

In survivors during follow-up (2–3-year postdiagnosis; n = 829)

Never

 <25

26/47

1.0

1.0

9/47

1.0

1.0

 25 ≤ 30

69/114

1.07 (0.68–1.68)

1.00 (0.63–1.58)

31/114

1.41 (0.67–2.97)

1.08 (0.50–2.34)

 30+

46/80

1.36 (0.84–2.21)

1.22 (0.73–2.03)

21/80

1.48 (0.67–3.23)

0.91 (0.39–2.13)

 Test for trend

 

0.19

0.41

 

0.37

0.75

Former

 <25

48/64

1.0

1.0

13/64

1.0

1.0

 25 ≤ 30

148/234

0.80 (0.57–1.11)

0.72 (0.51–1.01)

41/234

0.80 (0.43–1.49)

0.50 (0.25–0.96)

 30+

104/175

0.84 (0.59–1.19)

0.73 (0.51–1.05)

44/175

1.20 (0.64–2.52)

0.99 (0.51–1.90)

 Test for trend

 

0.51

0.19

 

0.23

0.22

Current

 <25

24/29

1.0

1.0

9/29

1.0

1.0

 25 ≤ 30

39/53

0.80 (0.48–1.34)

0.95 (0.56–1.62)

10/53

0.54 (0.22–1.36)

0.58 (0.21–1.57)

 30+

24/33

1.09 (0.60–1.96)

1.21 (0.66–2.23)

7/33

0.66 (0.24–1.83)

0.88 (0.29–2.65)

 Test for trend

 

0.81

0.55

 

0.41

0.81

  1. HR hazard ratio; CI confidence interval; BMI body mass index.
  2. aAdjusted for age at diagnosis (continuous), stage of cancer (T2; T3/4; missing), prostatectomy (yes; no), hormone therapy (yes; no), radiation therapy (yes; no), PSA levels at diagnosis (<4; 4–10; >10–20; >20), postdiagnosis Charlson comorbidity score (continuous), total average alcohol consumption (continuous), smoking status at diagnosis (current; former; and never), Gleason score at diagnosis (<7; ≥7) and average frequency of going for a general check-up (yearly; every few years; occasionally; missing).
  3. bAdjusted for age at diagnosis (continuous), stage of cancer (T2; T3/4; missing), prostatectomy (yes; no), hormone therapy (yes; no), radiation therapy (yes; no), PSA levels at diagnosis (<4; 4–10; >10–20; >20), postdiagnosis Charlson comorbidity score (continuous), total average alcohol consumption (continuous), region of residence (rural; urban), Gleason score at diagnosis (<7; ≥7) and average frequency of going for a general check-up (yearly; every few years; occasionally; missing)
Back to article page